BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

• XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne -- Over 30 million acne patients seek treatment in the U.S. each year -SAN DIEGO, March 26, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology compan ...